| abstract |
FIELD: biotechnology.SUBSTANCE: described is a group of inventions comprising an antibody-antibiotic conjugate compound for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophytics or Staphylococcus simulans, containing WTA (teichoic acid of cell wall) β antibody, a pharmaceutical composition for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans, method of treating bacterial infection in a patient infected with one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans, method for destroying intracellular Staphylococcus aureus in cells of a Staphylococcus aureus infected patient without killing host cells, a method for preparing an antibody-antibiotic conjugate compound, a kit for treating an infection, caused by Staphylococcus aureus, Staphylococcus saprophyticus and/or Staphylococcus simulans, and an antibiotic linker intermediate for preparing the antibody-antibiotic conjugate.EFFECT: invention extends the range of products for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans.29 cl, 17 dwg, 6 tbl, 21 ex |